Evidence map›Paper›PMID 37457706›Full record

ArticleFrontiers in immunology2023

PARP2 downregulation in T cells ameliorates lipopolysaccharide-induced inflammation of the large intestine.

Máté Bencsics, Bálint Bányai, Haoran Ke, Roland Csépányi-Kömi, Péter Sasvári, Françoise Dantzer, Najat Hanini, Rita Benkő, Eszter M Horváth

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The Flavonoid Extract ofAntioxidants (Basel, Switzerland) · 2025
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Máté BencsicsDepartment of Physiology, Semmelweis University, Budapest, Hungary.
Bálint BányaiDepartment of Physiology, Semmelweis University, Budapest, Hungary.
Haoran KeDepartment of Physiology, Semmelweis University, Budapest, Hungary.
Roland Csépányi-KömiDepartment of Physiology, Semmelweis University, Budapest, Hungary.
Péter SasváriDepartment of Physiology, Semmelweis University, Budapest, Hungary.
Françoise DantzerUMR7242, Biotechnology and Cell Signaling, CNRS/Université de Strasbourg, Strasbourg, France.
Najat HaniniUMR7242, Biotechnology and Cell Signaling, CNRS/Université de Strasbourg, Strasbourg, France.
Rita BenkőDepartment of Physiology, Semmelweis University, Budapest, Hungary.
Eszter M HorváthDepartment of Physiology, Semmelweis University, Budapest, Hungary.
Semmelweis University · HUCentre National de la Recherche Scientifique · FRUniversité de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: T cell-dependent inflammatory response with the upregulation of helper 17 T cells (Th17) and the downregulation of regulatory T cells (Treg) accompanied by the increased production of tumor necrosis alpha (TNFa) is characteristic of inflammatory bowel diseases (IBD). Modulation of T cell response may alleviate the inflammation thus reduce intestinal damage. Poly(ADP-ribose) polymerase-2 (PARP2) plays role in the development, differentiation and reactivity of T cell subpopulations. Our aim was to investigate the potential beneficial effect of T cell-specific PARP2 downregulation in the lipopolysaccharide (LPS) induced inflammatory response of the cecum and the colon. Methods: Low-dose LPS was injected intraperitoneally to induce local inflammatory response, characterized by increased TNFa production, in control (CD4Cre; PARP2+/+) and T cell-specific conditional PARP2 knockout (CD4Cre; PARP2f/f) mice. TNFa, IL-1b, IL-17 levels were measured by ELISA, oxidative-nitrative stress was estimated by immunohistochemistry, while PARP1 activity, p38 MAPK and ERK phosphorylation, and NF-kB expression in large intestine tissue samples were examined by Western-blot. Systemic & local T cell subpopulation; Th17 and Treg alterations were also investigated using flowcytometry and immunohistochemistry. Results: In control animals, LPS induced intestinal inflammation with increased TNFa production, while no significant elevation of TNFa production was observed in T cell-specific PARP2 knockout animals. The absence of LPS-induced elevation in TNFa levels was accompanied by the absence of IL-1b elevation and the suppression of IL-17 production, showing markedly reduced inflammatory response. The increase in oxidative-nitrative stress and PARP1-activation was also absent in these tissues together with altered ERK and NF-kB activation. An increase in the number of the anti-inflammatory Treg cells in the intestinal mucosa was observed in these animals, together with the reduction of Treg count in the peripheral circulation. Discussion: Our results confirmed that T cell-specific PARP2 downregulation ameliorated LPS-induced colitis. The dampened TNFa production, decreased IL-17 production and the increased intestinal regulatory T cell number after LPS treatment may be also beneficial during inflammatory processes seen in IBD. By reducing oxidative-nitrative stress and PARP1 activation, T cell-specific PARP2 downregulation may also alleviate intestinal tissue damage.

Indexed as

Inflammatory Bowel DiseasesLipopolysaccharidesAnimalsColonDown-RegulationInflammationInterleukin-17MiceNF-kappa BPoly(ADP-ribose) PolymerasesT-Lymphocytes, RegulatoryInterleukin-17LipopolysaccharidesNF-kappa BPoly(ADP-ribose) PolymerasescolitisIBD - inflammatory bowel diseasePARP2PARP (poly(ADP-ribose) polymeraseregulatory (Treg) cellT lymphocyte

Identifiers

PMID37457706
PMCPMC10347374
OpenAlexW4382776606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.